Tabone M D, Landman-Parker J, Arcil B, Coudert M C, Gerota I, Benbunan M, Leverger G, Dosquet C
Service d'Hématologie et d'Oncologie Pédiatrique, H pital d'Enfants Armand Trousseau, Paris, France.
Clin Cancer Res. 2001 Mar;7(3):538-43.
Angiogenesis plays an important role in the growth, progression, and metastasis of solid tumors. Among angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) appear to be useful markers in adults with cancer. The aim of this pilot study was to determine the levels of VEGF in serum and bFGF in serum and urine of children with solid tumor at diagnosis (as measured by ELISA), and to investigate whether these parameters provide prognostic information. Forty consecutive patients with different types of cancer were prospectively included in this study. Median values of all studied angiogenic factors were higher in patients than in controls (n = 40), and the differences were statistically significant for bFGF in serum and urine: 10 versus 3 pg/ml (P = 0.0004) and 6406 versus 0 pg/g of creatinine (P < 0.0001), respectively. Among patients, median serum values of bFGF and VEGF were higher in children with metastatic disease (n = 14) than in those with localized disease (n = 26). The difference was statistically significant for serum bFGF: 17.5 versus 6 pg/ml (P = 0.02). Serum angiogenic factor levels correlated with outcome. The estimated event-free survival at 3 years was 79% for patients with normal bFGF values (n = 13) versus 42% (n = 26; P = 0.02) for those with high levels, and 71% in case of normal VEGF values (n = 20) versus 38% (n = 19; P = 0.04) for those with high levels. No benefit of normal urinary bFGF values was observed. Our results provide a rationale for exploring the clinical interest of bFGF and VEGF measurements in body fluids of a larger group of children with cancer.
血管生成在实体瘤的生长、进展和转移过程中发挥着重要作用。在血管生成因子中，碱性成纤维细胞生长因子（bFGF）和血管内皮生长因子（VEGF）似乎是成年癌症患者有用的标志物。这项初步研究的目的是测定实体瘤患儿诊断时血清中VEGF以及血清和尿液中bFGF的水平（通过酶联免疫吸附测定法进行测量），并研究这些参数是否能提供预后信息。本研究前瞻性纳入了40例连续的不同类型癌症患者。所有研究的血管生成因子的中位数在患者中均高于对照组（n = 40），血清和尿液中bFGF的差异具有统计学意义：分别为10 pg/ml对3 pg/ml（P = 0.0004）和6406 pg/g肌酐对0 pg/g肌酐（P < 0.0001）。在患者中，转移性疾病患儿（n = 14）的血清bFGF和VEGF中位数高于局限性疾病患儿（n = 26）。血清bFGF的差异具有统计学意义：17.5 pg/ml对6 pg/ml（P = 0.02）。血清血管生成因子水平与预后相关。bFGF值正常的患者（n = 13）3年无事件生存率估计为79%，而高水平患者为42%（n = 26；P = 0.02），VEGF值正常的患者（n = 20）为71%，高水平患者为38%（n = 19；P = 0.04）。未观察到尿bFGF值正常带来的益处。我们的结果为探索在更大规模的癌症患儿体液中测量bFGF和VEGF的临床意义提供了理论依据。
